AbbVie, a research-based global biopharmaceutical company, announced that the FDA approved SKYRIZI™ for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Read the full announcement by AbbVie.
Read more about FDA Approves New Topical Treatment for Atopic Dermatitis
Read about advances in Serborrheic Keratosis on the Global Academy for Medical Education website.
Five common pitfalls of retailing skin care
FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis- click HERE to read more!
Could New CBD Cream Could Be Ultimate Cure For Acne?
Psoriasis is not a cosmetic problem. Nearly 60 percent of people with psoriasis reported their disease to be a large problem in their everyday life. DS Research is currently conducting various research studies for the treatment of plaque psoriasis as well as itching that is associated with psoriasis. To learn more about these statistics involving… Read More
In recent years, research into other autoimmune diseases brought new insights about the immune system. It turns out that some of the problems in those conditions are active in psoriasis, as well. The new info brought treatments that target specific areas of your immune system. Called biologics, these drugs launched a new era of psoriasis… Read More
Click HERE to read more!
Eskata approved for the treatment of patients with Seborrheic Keratoses that are raised. To read more click HERE